Prevention, diagnosis and treatment of @entity8 are continually evolving. We submitted a postal questionnaire to all Spanish dialysis centres, comprising 30 questions, with the aim of obtaining information about the current management of this entity in Spain. The answers from 171 centres, 63% of the total registered (10,724 @entity1 ), were analysed. The centres performed an annual average of nine @entity460 and @entity3151 determinations, three for @entity461 ( @entity461 ), 1.5 for @entity5715 and one for bone radiology. For these parameters, nephrologists consider ideal levels to be 10-10.5 mg/dl for @entity460 (53% of centres), 4.5-5.5 mg/dl for @entity3151 (77%) and 120-150 pg/ml for iPTH (75%). The @entity460 concentration used in the dialysis fluids was found to be variable: 2% of the centres used 2 mEq/l, 44% used 2.5 mEq/l, 28% used 3 mEq/l and 26% used 3.5 mEq/l. When using oral @entity3873 , 82% of the centres do not change the @entity460 concentration in the dialysis fluids; this percentage falls to 51% when @entity3873 administration is parenteral. In 78% of centres, @entity560 treatment was started when @entity461 was high, without taking into consideration the plasma @entity460 level. The dose varies; in 28% of the centres @entity3873 pulse therapy was started when iPTH was >250 pg/ml; 52% when >500 pg/ml and 16% when >750 pg/ml. Seventy one percent of the centres claim to use @entity3873 in doses proportional to the severity of @entity2742 . With regard to response to treatment, 78% of the centres wait for 6 months before considering a @entity1 as a 'non-responder' and 80% of the centres would carry out parathyroidectomy only when iPTH is >750 pg/ml. The data collected from the enquiry show that there are important variations in some aspects related to current @entity1 management in the different units in Spain. Diagnostic criteria are relatively homogeneous whereas the therapeutic guidelines are less uniform.

Prevention, diagnosis and treatment of XXXX in Spain. Preliminary results from a multicentre enquiry.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal osteodystrophy'] @entity3873 :: ('MESH:D002117', 'Chemical') :: ['calcitriol'] @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium'] @entity3151 :: ('MESH:D010758', 'Chemical') :: ['phosphorus'] @entity2742 :: ('MESH:D006961', 'Disease') :: ['hyperparathyroidism'] @entity461 :: ('5741', 'Gene') :: ['PTH', 'parathyroid hormone'] @entity5715 :: ('CHEBI:28984', 'Chemical') :: ['aluminium'] @entity560 :: ('MESH:D014807', 'Chemical') :: ['vitamin D']
@entity8 :: (MESH:D007674,Disease) :: ['renal osteodystrophy']
